High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.

Thorac Cancer · 2019 · PMC6775002 · PMID 31482678

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

showed a trendP = 0.11not close (p > 0.1)

A one‐month landmark analysis showed a trend toward better median OS in the patients with severe grade CIP (6.0 [95% CI 2.0–18.0] months vs. 13.0 [12.0–21.0] months, P = 0.11, N = 65; Fig 3 a,b).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.